HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study M Grau-Vorster, A Laitinen, J Nystedt, J Vives Stem cell research & therapy 10, 1-8, 2019 | 64 | 2019 |
Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly I Oliver-Vila, MI Coca, M Grau-Vorster, N Pujals-Fonts, M Caminal, ... Cytotherapy 18 (1), 25-35, 2016 | 57 | 2016 |
Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells I Oliver-Vila, C Ramírez-Moncayo, M Grau-Vorster, S Marín-Gallén, ... Cytotechnology 70, 31-44, 2018 | 30 | 2018 |
Compliance with good manufacturing practice in the assessment of immunomodulation potential of clinical grade multipotent mesenchymal stromal cells derived from Wharton’s Jelly M Grau-Vorster, L Rodríguez, A del Mazo-Barbara, C Mirabel, M Blanco, ... Cells 8 (5), 484, 2019 | 27 | 2019 |
Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow–derived multipotent mesenchymal stromal cell expansion cultures M Grau-Vorster, L Rodríguez, S Torrents-Zapata, D Vivas, M Codinach, ... Cytotherapy 21 (1), 32-40, 2019 | 25 | 2019 |
Characterization of a cytomegalovirus-specific T lymphocyte product obtained through a rapid and scalable production process for use in adoptive immunotherapy M Grau-Vorster, M López-Montañés, E Cantó, J Vives, I Oliver-Vila, ... Frontiers in immunology 11, 271, 2020 | 11 | 2020 |
Evaluation of a cell-based osteogenic formulation compliant with good manufacturing practice for use in tissue engineering D Vivas, M Grau-Vorster, I Oliver-Vila, J García-López, J Vives Molecular Biology Reports 47 (7), 5145-5154, 2020 | 5 | 2020 |
Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton’s Jelly … M Grau-Vorster, L Rodríguez, A Del Mazo-Barbara, C Mirabel, M Blanco, ... | 5 | |
Illustrative Potency Assay Examples from Approved Therapies S Torrents, M Grau-Vorster, J Vives Potency Assays for Advanced Stem Cell Therapy Medicinal Products, 139-149, 2023 | 1 | 2023 |
Off-the-shelf mesenchymal stromal cells derived from umbilical cord tissue I Oliver-Vila, MI Coca, M Grau-Vorster, N Pujals-Fonts, M Caminal, A Pla, ... BMC Proceedings 9 (Suppl 9), P65, 2015 | 1 | 2015 |
Potency Assays: The ‘Bugaboo’of Stem Cell Therapy S Torrents, M Grau-Vorster, J Vives Potency Assays for Advanced Stem Cell Therapy Medicinal Products, 29-38, 2023 | | 2023 |
Development and characterisation of advanced cell therapies based on multipotent mesenchymal stromal cells and virus-specific T lymphocytes M Grau-Vorster | | 2020 |
HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells M Grau-Vorster, A Laitinen, J Nystedt, J Vives Armengol | | 2019 |
Optimization of methods for ex vivo expansion of T-cells for adoptive immunotherapy M Grau-Vorster, A del Mazo-Barbara, D Vivas-Pradillo, C Mirabel, ... Cytotherapy 19 (5), S36, 2017 | | 2017 |
number of doses of CMV-specific cytotoxic T cells was successfully performed. M Grau-Vorster, M López-Montañés, E Cantó, J Vives, I Oliver-Vila, ... | | |